ALP Bio raises CHF 1.8 M

ALP Bio combines human immune organoids with generative AI to reduce the immunogenicity risk of therapeutic antibodies. The Schlieren-based company has raised CHF 1.75 million in pre-seed funding, led by 42CAP.

Announced on
Round
Pre-seed
Amount
CHF 1.8 M
Location
Schlieren, canton of Zurich
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic